Industry Satellite Symposia webcasts

09/09/2022

Janssen-Cilag International NV
Catching it early, getting it right: optimal disease and patient management from biomarkers to treatment selection

Watch session

• Welcome and Introduction
  Maria De Santis
• Patient case presentation and discussion: From the pathologist's and urologists' perspectives
  Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
• Patient case analysis: how do we select the best treatment in challenging cases?
  Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
• Treatment selection and managing patients safety: a discussion on the treatment landscape
  Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
• Audience Q&A
  Maria De Santis, Thomas B. Powles, Eva Comperat, Shahrokh F. Shariat
• Summary and close
  Thomas Powles

Bristol Myers Squibb
GI Cancer and Immuno-Oncology Today: Best Practice and Clinical Challenges

Watch session

• Welcome and Introduction
  Myriam Chalabi
• Current Status of I-O for Treating CRC
  Myriam Chalabi
• Treating Gastric Cancer Today: I-O-focused Update
  Kei Muro
• Emerging Treatments for Esophageal Cancer:  First-Line Metastatic Disease and Earlier Stages
  Emmanuelle Samalin-Scalzi
• Roundtable Case Discussion, Q&A, and Summary
  Ian Chau
• Close
  Ian Chau

F. Hoffmann-La Roche Ltd
Navigating the possibilities of personalised healthcare in oncology

Watch session

• A guide to the expanding possibilities in personalised healthcare
  Allan Hackshaw
• Cancer of unknown primary: Making the unknown known
  Alwin Krämer
• Panel discussion: Progress in personalised healthcare
  Allan Hackshaw, Alwin Krämer, Jean-Yves Blay, Charles Alessi, Warnyta Minnaard
• Staying at the frontier of comprehensive genomic profiling and liquid biopsy
  Jean-Yves Blay
• The value of real-world data for augmenting personalised healthcare at several levels
  Allan Hackshaw
• Panel discussion: Putting the possibilities into practice
  Allan Hackshaw, Jean-Yves Blay, Alwin Krämer, Charles Alessi, Warnyta Minnaard
• Conclusion
  Allan Hackshaw

PeerView Oncology
Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

Watch session

• Welcome and Introduction
  Aleix Prat
• Understanding the Foundational Concepts of HER2-Low Breast Cancer: Challenges and Opportunities of an Evolving Definition
  Paolo Tarantino
• Extending Anti-HER2 Therapy Benefits to a Larger Population of Patients: Emerging Evidence, Implementation in Clinical Practice, and Future Directions
  Shanu Modi
• Unveiling the Biology of HER2-Low Breast Cancer: Insights From Genomics, Transcriptomics, and Opportunities With Evolving Testing Approaches
  Aleix Prat
• Exploring the Nuances of HER2-Targeted Treatment Selection for Patients With HER2-Low Breast Cancer: Expert Insights Into Implications for Practice and Team-Based Approaches to Individualizing Patient Care
  Aleix Prat
• Summary, Reflections, and Key Takeaways
  Aleix Prat

Servier
Interpreting real-world data to better manage patients with metastatic colorectal cancer

Watch session

• Introduction
  Julien Taieb
• Is there a need for real-world data?
  Chiara Cremolini
• Real-world data in mCRC
  Miriam Koopman
• Patient insights and perspectives on real-world data
  Francisca E. Marti
• Optimization and management of treatment in mCRC
  Dominik P. Modest
• Conclusion and Q&A
  Julien Taieb

10/09/2022

GSK
Avant-garde: Reframing the art of first-line maintenance therapy to optimise long-term outcomes in advanced ovarian cancer

Watch session

• Welcome and introduction
  Gilles Freyer
• State of the art: What are the most current data and updates to treatment guidelines for first-line maintenance in ovarian cancer
  Domenica Lorusso
• The art of treatment selection: Importance and impact of early treatment planning
  Charlie Gourley
• Articles of individualised treatment: How can we begin to individualise treatment using biomarkers and available therapies
  Gilles Freyer
• Closing remarks
  Gilles Freyer

Boehringer Ingelheim International GmbH
Breaking Through the Firewall: New Therapeutic Strategies to Disrupt Cancer’s Operating Systems

Watch session

• Welcome and Introductions
  Martin Reck
• Development of an MDM2-p53 Antagonist for STS and Other Indications
  Patrick Schoeffski
• Targeting HER2 and KRAS to Deliver Breakthrough Therapies
  Egbert F. Smit
• T-cell Engagers: Change of the Treatment Paradigm in Solid Tumors
  Martin Reck
• Expert Panel Q&A
  Martin Reck, Patrick Schoeffski, Egbert F. Smit
• Closing Remarks
  Martin Reck

PeerVoice
Contemporary Management of Prostate Cancer: Updated Approaches for Improved Outcomes in nmCRPC and mHSPC

Watch session

• Welcome, Faculty Introductions, and Overview of Agenda
  Karim Fizazi
• State-of-the-Art Interventions in mHSPC: New Evidence, New Expectations
  Karim Fizazi, Alicia K. Morgans, Bertrand Tombal
• Modernising the Standard of Care in nmCRPC: What Are We Waiting For?
  Karim Fizazi, Alicia K. Morgans, Bertrand Tombal
• Key Questions and Expert Discussion With Programme Faculty
  Karim Fizazi, Alicia K. Morgans, Bertrand Tombal
• Final Remarks, Conclusions, and Closing
  Karim Fizazi

Janssen-Cilag International NV
Exploring questions in metastatic prostate cancer 

Watch session

• Welcome and introduction
  Laura-Maria Krabbe
• Question 1: How should we manage oligometastatic disease?
  Joe O'Sullivan
• Question 2: What is the role of chemotherapy alongside hormonal treatments in mHSPC?
  Gerhardt Attard, Laura-Maria Krabbe
• Question 3: How do we choose treatment options for patients with mCRPC?
  Eleni Efstathiou
• Close
  Gerhardt Attard

Janssen-Cilag International NV
Precision approaches in EGFR-mutant NSCLC: Optimising outcomes for patients

Watch session

• Welcome & Introduction
  David Planchard
• Updates in precision approaches to the molecular diagnosis of NSCLC
  Paul Hofman
• Discussion: How can we address diagnostic challenges of NSCLC in clinical practice?
  David Planchard, Maria Rosario Garcia Campelo, Sanjay Popat, Anne-Marie C. Dingemans, Paul Hofman
• New and emerging therapies for EGFR-mutant NSCLC
  Anne-Marie C. Dingemans
• Discussion: What does the future hold for the management of EGFR-mutant NSCLC?
  David Planchard, Maria Rosario Garcia Campelo, Sanjay Popat, Anne-Marie C. Dingemans, Paul Hofman
• Emerging treatment options for EGFR exon 20 insertions
  Sanjay Popat
• Q&A
  David Planchard, Maria Rosario Garcia Campelo, Sanjay Popat, Anne-Marie C. Dingemans, Paul Hofman
• Key learnings and closing remarks
  Maria Rosario Garcia Campelo

BeiGene Switzerland GmbH
Standard of Care is Not Enough! Talking Immunotherapy Clinical Trials in GI Cancers

Watch session

• Welcome to the Conversation
  Lesley J. Fallowfield
• What Now Doc? A Patient’s Perspective
  Tihana Gašpert
• GI Cancers: Checkpoint Inhibitors and Beyond
  Elizabeth Smyth
• Talking With Patients About Clinical Trials: How, What, Why, When and Where?
  Lesley J. Fallowfield
• Questions about Trials? Connect With your Expert!
  Elizabeth Smyth, Eric Van Cutsem, Michel P. Ducreux, Sylvie Lorenzen, Stefano Cascinu
• Chairs’ Conclusions
  Lesley J. Fallowfield, Elizabeth Smyth

Medscape Oncology Global
Improving Outcomes in Patients With High-Risk HR+/HER2- EBC: Keeping the Patient Central

Watch session

• Welcome and introduction 
  Joyce O'Shaughnessy
• How Would You Assess Risk of Recurrence in This Patient With HR+/HER2- EBC? Patient video will be included
  Wolfgang Janni
• Treatment Considerations for Patients With High-Risk HR+/HER2- EBC: What do the Latest Data Show?
  Miguel Martin Jimenez
• Keeping the Patient Central: Discussing Adherence and Persistence and the Role of the MDT Patient
  Sarah Donahue
• Concluding Remarks
  Joyce O'Shaughnessy

Bristol Myers Squibb
The Treatment Paradigm Shift: Unlocking New Chapters with I-O in Thoracic Cancers

Watch session

• Welcome and Introductions
  Virginie Westeel
• Multidisciplinary Conversation: Putting I-O on the Table for Patients with Resectable NSCLC
  Jonathan Spicer
• Considering the Options: Survivorship in Metastatic NSCLC and Potential Approaches for I-O–Experienced Patients
  Virginie Westeel
• Making Progress for Patients: How I-O Has Changed Outcomes in Unresectable MPM
  Dean Fennell
• Live Q&A and Closing Remarks
  Dean Fennell

11/09/2022

Ipsen
Disrupting the landscape: the Plus One in RCC and NSCLC

Watch session

• Welcome & agenda
  Laurence Albiges
• Triple, double and monotherapy: what is the sequence for best outcomes?
  Jens Bedke, Guillermo Antonio De Velasco Oria, Sumanta K. Pal
• Expanding the armamentarium with IO-TKIs combinations – what can be learnt from RCC for the future of NSCLC?
  Laurence Albiges, Luis Paz-Ares, Sumanta K. Pal, Jens Bedke, Guillermo Antonio De Velasco Oria
• Unmet needs in NSCLC: targeting second-line treatment with TKI-IO
  Luis Paz-Ares
• Closing
  Laurence Albiges

GSK
Immune Checkpoint Inhibitors in Mismatch Repair Deficient Solid Tumors: Expert Interviews

Watch session

• Clinical considerations for ICI treatment of dMMR endometrial cancer and other dMMR solid tumors
  Isabelle L. Ray-Coquard, Alexandra Leary, Andrea Cercek
• Chair interview of Dr. Leary: Perspective on identifying patients with dMMR endometrial cancer for ICI treatment
  Alexandra Leary
• Chair interview of Dr. Cercek: Perspective on single-agent PD-1 blockade in dMMR CRC/solid tumors
  Andrea Cercek
• Panel discussion: Considerations for ICI treatment of dMMR endometrial cancer and CRC/solid tumors, expert perspectives
  Isabelle L. Ray-Coquard, Alexandra Leary, Andrea Cercek
• Q&A
  Isabelle L. Ray-Coquard, Alexandra Leary, Andrea Cercek

F. Hoffmann-La Roche Ltd
Redefining Lung Cancer Together: Now and Next

Watch session

• Welcome and Introduction
  Stephen Liu
• Patient perspective: Where are we now?
  Stefania Vallone
• Biomarkers in lung cancer: challenges and opportunities
  Frederique Penault-Llorca
• Immunotherapy, targeted therapy and beyond: navigating options for metastatic disease
  Stephen Liu, Martin Reck
• Treatment choice in early-stage lung cancer: new insights, new outlooks
  Martin Reck, Paul E. Van Schil
• Panel discussion and Q&A
  Stephen Liu, Martin Reck, Frederique Penault-Llorca, Paul E. Van Schil, Stefania Vallone
• Conclusion
  Stephen Liu, Stefania Vallone

Servier
Understanding the treatment strategy in metastatic pancreatic cancer to improve patient outcomes

Watch session

• Introduction
  Thomas Seufferlein
• Treatment planning strategy in mPAC
  Christoph Benedikt Westphalen    
• Real-world data in mPAC
  Marc Peeters    
• Insights from Japan in mPAC
  Masafumi Ikeda
• Long-term survivors
  Teresa Macarulla Mercade
• Panel discussion
  Teresa Macarulla Mercade, Thomas Seufferlein
• Conclusion
  Thomas Seufferlein

Astellas
The maturing treatment landscape of mHSPC

Watch session

• Welcome and introduction
  Stephane Oudard
• Reap what you sow: Treatments for mHSPC in use today
  Ian D. Davis
• Forget-me-nots: Unmet needs in mHSPC
  Shahrokh F. Shariat
• The grass is greener: Deciding on the most appropriate initial treatment for patients with mHSPC
  Heather Payne
• Q&A
  Stephane Oudard, Ian D. Davis, Heather Payne, Shahrokh F. Shariat
• Closing remarks
  Stephane Oudard

12/09/2022

Medscape Oncology Global
Targets of Antibody-Drug Conjugates in NSCLC: Diagnostics, Emerging Therapies, and Future Prospects

Watch session

• Personalizing Treatment in NSCLC: Recent Developments
  Enriqueta Felip
• Novel ADC Targets in NSCLC: Rationale and Diagnostic Considerations
  Michael Thomas
• Which Patients May Benefit From Emerging ADCs in NSCLC: Explaining the Clinical Trial Data
  Egbert F. Smit
• Preparing the Clinics and Future Prospects
  Enriqueta Felip
• Q&A Session
  Enriqueta Felip, Michael Thomas, Egbert F. Smit
• Concluding Remarks
  Enriqueta Felip

F. Hoffmann-La Roche Ltd
What, why and how: Expert review and opinions on the potential of oral SERDs for our patients with HR+ BC

Watch session

• Welcome and Introduction
  Nick Turner
• What are oral SERDs and why do our patients need them?
  Komal Jhaveri
• What have we seen from oral SERDs and what could they mean for our patients in future?
  Aditya Bardia
• What’s next for oral SERDs and beyond for our patients with HR+ disease?
  Nick Turner
• Q&A
  Nick Turner, Komal Jhaveri, Aditya Bardia
• Close
  Nick Turner

Astellas Pharma Europe Ltd
Navigating the evolving landscape of locally advanced unresectable or metastatic G/GEJ adenocarcinoma

Watch session

• Welcome and introductions
  Hanneke W. Van Laarhoven
• The current landscape for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
  Hanneke W. Van Laarhoven
• Emerging treatments for locally advanced unresectable or metastatic G/GEJ adenocarcinoma
  Eric Van Cutsem
• Working together in an evolving therapeutic landscape
  Hanneke W. Van Laarhoven, Mar Iglesias, Eric Van Cutsem
• Q&A session
  Hanneke W. Van Laarhoven, Mar Iglesias, Eric Van Cutsem
• Meeting summary and close
  Hanneke W. Van Laarhoven

Bristol Myers Squibb
The Evolving Treatment Landscape for Metastatic Melanoma: A Clinical Lens on Current Decision Making

Watch session

• Welcome and introduction
  Paolo A. Ascierto
• Emerging Data for the First-line Treatment of Metastatic Melanoma
  Nicolas Meyer
• Considerations for Treatment Selection: A Case-Based Panel Discussion
  Hussein A. Tawbi
• The Melanoma Continuum of Care: Remaining Challenges and Unmet Needs
  Paolo A. Ascierto
• Summary and close
  Paolo A. Ascierto

Bristol Myers Squibb
Navigating the Integration of Immuno-Oncology Into the Perioperative Muscle-Invasive Urothelial Carcinoma Treatment Landscape

Watch session

• Welcome and Introduction
  Andrea Necchi
• The MIUC Treatment Landscape in 2022
  Morgan Roupret
• Opportunities for I-O Use in the Perioperative Setting
  Margitta Retz
• Optimising Patient Treatment: Perspectives on the Future Treatment Landscape
  Andrea Necchi
• Interactive Multidisciplinary Team Meeting
  Andrea Necchi, Morgan Roupret, Margitta Retz
• Q&A
  Andrea Necchi, Morgan Roupret, Margitta Retz     
• Summary and Close
  Andrea Necchi

Seagen
Expert Opinion: Considerations for Managing HER2+ Breast Cancer and Brain Metastases

Watch session

• Welcome and Introduction
  Diana I. Lüftner
• The HER2+ breast cancer pathway
  Olivier Trédan
• Managing brain metastases
  Pierfranco Conte
• Brain metastases: challenging current perceptions
  Icro Meattini
• Conclusions
  Diana I. Lüftner